COMBINATION OF TGR‐1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA. (June 2017)